(1R,9S,14S,18E,21S,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酯内酰胺
• 英文名称: (1R,9S,14S,18E,21S,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
• 化学式: C₄₄H₆₉NO₁₂
• 分子量: 804.0
• InChiKey: QJJXYPPXXYFBGM-GMXRAPKLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  57
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  178
• 氢给体数：
  3
• 氢受体数：
  12

文献信息

• TACROLIMUS AND ANALOGUES THEREOF FOR MEDICAL USE
  申请人：CHRONOS THERAPEUTICS LIMITED

  公开号：US20160120853A1

  公开（公告）日：2016-05-05

  The present invention relates to a method of treating adverse fat accumulation and related conditions with very low doses of tacrolimus or a close structural analogue thereof. In particular this invention relates to treating adverse fat accumulation and/or sarcopenia and/or metabolic syndrome inpatients by administering tacrolimus in very low dose. Most particularly this invention relates to the use of tacrolimus in treating age related fat accumulation.
• TACROLIMUS FOR USE IN TREATING DISEASES CHARACTERIZED BY PROTEIN AGGREGATE DEPOSITION IN NEURONAL CELLS
  申请人：CHRONOS THERAPEUTICS LIMITED

  公开号：US20160296500A1

  公开（公告）日：2016-10-13

  This invention relates to the use of a very low dose of tacrolimus or a close structural analogue to treat a disease characterised by deposition of protein aggregates in neuronal cells. More particularly this invention relates to the use of a very low dose of tacrolimus for the treatment of amyotrophic lateral sclerosis.